Filer	Title/Relationship	Filing Date	Planned Shares	Est. Value
Koenig Sheldon L.	Officer, Director	2026-06-17	54K shares	$169K
Halladay Benjamin	Officer	2026-06-17	11K shares	$34K
Looker Benjamin	Officer	2026-06-17	12K shares	$37K

Form 144 is a planned sale notice, not an executed transaction. Form 144 Tracker。

Beneficial Ownership (13D/13G)

Active 5%+ Holders

Data as of 2026-07-14

Reporting Person	Type	Filing Date	Shares	% of Class
Wasatch Advisors LP	13G/A	2026-07-14	1.93M	0.7%

View all Schedule 13D/13G filings

Material Events (8-K)

Filings (14d)

Data as of 2026-07-13

2026-07-13

Esperion Therapeutics entered into a Contingent Value Rights (CVR) agreement in connection with its merger, giving holders the right to receive up to $100 million in aggregate cash payments if certain milestones are achieved. It also amended its convertible notes so that each $1,000 principal amount converts into $1,032.68 cash plus 326.7974 CVRs, or after a make-whole fundamental change, $1,232.62 cash plus 390.0701 CVRs. Additionally, Esperion entered into a loan agreement with MergerCo, Parent, and lenders including BioPharma Credit PLC.

View Full Filing (SEC EDGAR)

2026-07-08

Esperion Therapeutics shareholders voted at a special meeting on July 8, 2026 to adopt the merger agreement with Essence Parent Inc. and its subsidiary. The deal received roughly 135.3 million votes in favor and 22.8 million against. Shareholders also approved, on a non-binding basis, the compensation for the company's executives tied to the merger.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding ESPERION THERAPEUTICS INC (ESPR)?

Major stakeholders currently include BlackRock, Inc. ($48.9M), Wasatch Advisors LP ($43.2M), Two Seas Capital LP ($31.2M). Based on the latest 13F filings, there are a total of 206 tracked investment funds and institutions maintaining positions in ESPR.

What is the overall institutional sentiment toward ESPR recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $88.9M, driven by 98 managers accumulating shares while 94 reduced their exposure.

Which institutions have been selling or reducing their ESPR positions?

In the latest period, 63 funds trimmed their holdings, and 31 managers completely exited their positions. The aggregate reported sell value was $232.3M.

Are there any notable investors adding ESPR to their portfolios?

Yes, buying activity remains notable. 33 institutions opened new positions in {ticker}, and 65 existing holders added to their shares. The total reported buy value for the quarter amounted to $327.8M.